VEGFB and type 2 diabetes mellitus: In muscle, VEGF-B has been shown to control lipid accumulation through regulation of endothelial fatty acid (FA) transcytosis, and it may thus be a potential target in treating type 2 diabetes (T2DM) (31) VEGF-B was overexpressed in podocytes, while VEGFR1 was mainly found to be expressed on endothelial cells.